enVVeno Medical Corporation (NVNO)
NASDAQ: NVNO · Real-Time Price · USD
2.740
+0.010 (0.37%)
Apr 25, 2025, 4:00 PM EDT - Market closed
enVVeno Medical Employees
enVVeno Medical had 37 employees as of December 31, 2024. The number of employees increased by 6 or 19.35% compared to the previous year.
Employees
37
Change (1Y)
6
Growth (1Y)
19.35%
Revenue / Employee
n/a
Profits / Employee
-$589,703
Market Cap
47.96M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NVNO News
- 4 days ago - VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium - Accesswire
- 11 days ago - enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment - Accesswire
- 27 days ago - The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium - Accesswire
- 2 months ago - enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25 - Accesswire
- 2 months ago - enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - Accesswire
- 2 months ago - One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum - Accesswire
- 2 months ago - Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting - Accesswire
- 4 months ago - enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe - Accesswire